## **Review Article:**





# Article Type: The title of paper, Capitalize first letters

First Author 1\* , Second Author 2



Insert the orchid code of the first author and the Correspondence author

#### Affiliation (Department, School/College, Institution/University, City/State-Country)

- 1. Department of Medical Laboratory Science, Shahid Beheshti University of Medical Science, Tehran, Iran.
- 2. School of Allied Medical Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran.



Cite this article as: Chegni H, Entezari S. Design, Effectiveness, Limitations and Future Perspectives of CAR-T Cells: A Review Article. 2022; 13(1):E38054. https://doi.org/10.22037/aab.v13i.38054



doi https://journals.sbmu.ac.ir/aab/article/view/38054



#### Article info: Received: 05 Apr 2022 Accepted: 14 May 2022 Published: 28 May 2022



#### \* Corresponding author:

Correspondence Author, PhD.

Address: Department of Medic Laboratory Science, Shahid Behes University of Medical Scient Tehran, Iran.

#### E-mail:

H.chegini2010@yahoo.com

Context: Targeted anti-cancer approaches bring about individual therapies to combat the complexity of most malignancies and enhance their chances of success. Currently, immunotherapy, which exploits the patient's immune system to fight the disease, has made a significant progress in the success rate of cancer treatment. T lymphocytes are one of the most powerful arms of the immune system against cancer cells; however, many tumor cells can escape by hiding their peptide antigens.

Evidence Acquisition: CAR-T cells can detect tumor cells' HLA without any restrictions. Promising outcomes from CAR-T cell clinical trials have increased hope among cancer patients, making CAR-T cell a prospective treatment for most cancers. However, its unique toxicities and the possibility of recurrence have raised concerns among scientists.

Results: Therefore, in this review, in addition to the design of CAR-T cells, we intend to discuss the process of CAR-T cell therapy in the treatment of malignancies and explore its disadvantages, advantages, and prospects.

Conclusion: Despite extensive studies, it is not yet possible to confirm the role of CAR-T cells, but based on the experience of applying CAR-T cells, a definite treatment is feasible through immunotherapy and strengthening the immune system.

Keywords: Adoptive immunotherapy, CAR-T cells, CAR-T cell toxicity, Chimeric antigen receptors, Cytokine release syndrome

#### 1. **Context**

(Headings: 14 pt, text: 12 pt) References should be numeric and in Brackets [1]. includes 1 or 2 sentences describing the clinical question or issue and its importance in clinical practice or public health.

describes the data sources, including the research strategies, time of the study, and other sources of the materials used such as subsequent reference searches of retrieved articles. It explains the methods used for quality assessment and inclusion of the identified articles.

## 2. Evidence Acquisition:

Table 1. Some studies have shown results in clinical trials of CAR-T cell (Book Antiqua 9 pt.)

Author	Targeted antigen	Disease	Phase	NO. of patients	Outcome
Li et al. [47]	ВСМА	RRMM and plasma cel leukemia	Phase 1 clinical trial	30	CRR: 43.3% Objective response rate: 90%
Madduri et al. [48]	ВСМА	RRMA	Phase 1b/2 clinical trial	97	CRR: 55.7% Overall survival rate (OSR): 87.7%

#### 3. Results

addresses the major findings of the review in an evidence-based, objective, and balanced style, emphasizing the available highest-quality evidence.

Figures: Figures should be kept to a necessary minimum and their information should not be duplicated in the text. Figures must be supplied either as JPEG or TIFF. Photographs and radiological imaging must be high resolution (at least 300 dpi, or higher) and at least 10 x 10 cm large. All figures should be cited in the paper in a consecutive order as: Figure 2.

#### 4. Conclusion

clearly states the conclusions in order to answer the questions raised, if applicable, based on the conclusions of the available evidence, and it emphasizes how clinicians should apply the current knowledge.

#### **Ethical Considerations**

### Compliance with ethical guidelines

The ethical principles observed in the article, such as the informed consent of the participants, the confidentiality of information, the permission of the participants to cancel their participation in the research and the code of ethics received from the ethics committee of the universities should be written as follows:

a.All ethical principles are considered in this article. The participants were informed of the purpose of the research and its implementation stages. They were also assured about the confidentiality of their information and were free to leave the study whenever they wished, and if desired, the research results would be available to

them. A written consent has been obtained from the subjects. principles of the Helsinki Convention was also observed.

b.This study was approved by the Ethics Committee of the University of ??? (Code: ???).

c.This article is a meta-analysis with no human or animal sample.

d.There were no ethical considerations to be considered in this research.

**Sample**: This study was approved by the Ethics Committee of the jiroft University of medical science (Code IR.JMU.REC.1399.045)

### **Funding**

Was the paper extracted from a thesis? Or did it have any financial supporters? Kindly choose on of the below:

a.The paper was extracted from the MSc./ MA/ PhD. thesis or extracted from a research project of the first/second/third author, Department of ??? Faculty of??? University of ???

b.This research was supported by the research project (No. ???), Funded by the University of ???

c.This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

**Sample**: This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

#### Author's contributions

Please mention the contributor role of each author on

# Archives of Advances in Biosciences

this parts: Conceptualization, Methodology, Software, Validation, Formal Analysis, Investigation, Resources, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing, Visualization, Supervision, Project Administration, and Funding Acquisition.

The example below shows the Author Contributions:

Conceptualization and Supervision: Asghar Farhadi and Ibrahim Hassanpour; Methodology: Elahe Mahdavi; Investigation, Writing – original draft, and Writing – review & editing: All authors; Data collection: ???, ???, and ???; Data analysis: ??? and ???; Funding acquisition and Resources: Ibrahim Hassanpour, Elahe Mahdavi, Sima Kiani, and Reza Noori.

Or All authors equally contributed to preparing this article.

#### **Conflict of interest**

Declare conflicts of interest or state "The authors declare no conflict of interest." Authors must identify and declare any personal circumstances or interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. Any role of the funders in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results must be declared in this section. If there is no role, please state "The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results".

**Sample**: The Authors declare that there is no conflict of interest.

#### Acknowledgments

All logistic, financial, and technical assistance along with the nature of the support should be noted. You can thank the institution, laboratory, clinic, organizational affiliation, and/or those who contributed to the research. You may thank assistance with the patients, cells, supplies, animals, processes, data provision, referrals, and/or samples.

Financial resources should also be included in Acknowledgments. Full or partial investment and the information associated with the grant received, if applicable, need to be specified.

Sample I: This study was part of the first author's thesis. We would like to thank the Faculty of

Veterinary Medicine, Kazerun Branch of Islamic Azad University, for their help with data collection.

**Sample II**: We would like to extend our appreciation and thanks to all participants, staff, and managers who made this study possible.

Sample III: We are extremely grateful to Dr. Sarah Kahani for her comments and feedback during the study.

#### References

The reference numbers in the text should be in brackets. The DOI code and its link should be inserted separately at the end of each reference.

- [1] Johnson SB, Park HS, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst. 2018; 110(1):121-4. [DOI:10.1093/jnci/djx145] [PMID]
- [2] Mirzaei HR, Rodriguez A, Shepphird J, Brown CE, Badie B. Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications. Front Immunol. 2017; 8:1-13. [DOI:10.3389/fimmu.2017.01850] [PMID] [PMCID]
- [3] Noori Daloii MR, Rahimi Rad N, Kavoosi S. CAR T-cells: Novel targeted therapies in cancer. J Sabzevar Univ. 2018; 25(1):1-11. [https://www.sid.ir/en/Journal/ViewPaper .aspx?ID=604179]
- [4] Guedan S, Calderon H, Posey Jr AD, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019; 12:145-56. [DOI:10.1016/j.omtm.2018.12.009] [PMID] [PMCID]
- [5] Esmaeilzadeh A, Tahmasebi S, Athari SS. Chimeric antigen receptor-T cell therapy: Applications and challenges in treatment of allergy and asthma. Biomed Pharmacother. 2020; 123:109685. [DOI:10.1016/j.biopha.2019.109685]

#### In Review Article, the maximum number of

- references is 150
- illustrations or tables is 5
- words is 3500 (references included).